Background: Soluble intercellular adhesion molecule 1 (ICAM1) and C-X-C motif chemokine 13 (CXCL13) were described as differentially associated with two major subtypes of synovitis in rheumatoid arthritis (RA). Raised serum levels of ICAM1 (which is upregulated in synovial fibroblasts in response to TNFα) and of CXCL13 (which is expressed by synovial follicular dendritic cells and activated mature antigen-experienced T-helper cells), are associated with a myeloid or lymphoid synovial phenotype, respectively (1). It has been suggested that a preferential clinical response to anti-TNFα, as compared to anti-IL-6R monotherapy, can be predicted by measuring these two biomarkers (2). No information is available on the possible utility of these biomarkers in RA patients treated with abatacept (ABA), a T-cell co-stimulation blocker.

Objectives: To analyze the effect of ABA on ICAM1 and CXCL13 serum levels in RA and to verify whether they predict the response to the drug.

Methods: 63 RA patients [F/M=51/12; median (10th-90th percentile) age=60 (41-72) years; CRP-DAS28=4.6 (3.3-5.8); ACPA positive: 86%], before and after 6 months of treatment with ABA + methotrexate and 22 sex and age-matched healthy controls (HC) were evaluated. Serum ICAM1 and CXCL13 levels were dosed by commercial ELISA (Life Technologies and R&D). Response to treatment was defined with the EULAR criteria.

Results: CXCL13 serum levels were higher in RA than at baseline in HC [136 (42-325) vs 32 (19-57) pg/ml, p<0.01], while no difference was observed in ICAM1 [186 (125-276) vs 184 (153-246) ng/ml, p=0.9]; positive correlation was observed between ICAM1 and CRP (r=0.28, p=0.03) and CXCL13 levels and CRP (r=0.40, p=0.04); while no difference was observed in non-responders (222 (169-302) vs 186 (110-233) ng/ml, p=0.02). Not significant variation of ICAM1 serum levels was found in the entire cohort [186 (125-276) vs 184 (153-246) ng/ml, p=0.9]; positive correlations between ICAM1 and CRP (r=0.28, p=0.03) and CXCL13 levels and CRP (r=0.40, p=0.04); while no difference was observed in non-responders (222 (169-302) vs 186 (110-233) ng/ml, p=0.02). At baseline, no significant difference was found among patients seropositive for ACPA if compared with the negative ones [ACPAs vs ACPAs for ICAM1 [187 (123-280) vs 177 (134-258) pg/ml, p=0.7] and for CXCL13 [143 (42-368) vs 113 (32-248) pg/ml, p=0.9].

Conclusion: Our results confirmed that CXCL13 serum levels are directly correlated with disease activity and demonstrated that ABA therapy induces their reduction. These findings suggest that the co-stimulation blockade at central level and/or in the synovium lead to a reduced production of CXCL13. We could not demonstrate that CXCL13 levels predict the clinical response to ABA in this cohort of patients.

Acknowledgments: This study was sponsored by Corrona, LLC. Corrona is supported through contracted subscriptions with multiple pharmaceutical companies. The abstract was a collaborative effort between Corrona and Genentech, Inc., with financial support provided by Genentech, Inc.


DOI: 10.1136/annrheumdis-2020-eular.708

References:

FFR0105

RISK FACTORS FOR SERIOUS INFECTIONS IN PATIENTS WITH RA INITIATING TREATMENT WITH BIOLOGIC DMARDs: A REAL-WORLD POPULATION-BASED OBSERVATIONAL STUDY


1McGill University, Montreal, Canada; 2Bristol-Myers Squibb, Princeton, United States of America; 3Independent, Toms River, United States of America

Background: Various serious infections have been reported in patients with rheumatoid arthritis (RA) on biological DMARDs, including TNF inhibitors (TNFi), abatacept (ABA) and other biological DMARDs. Several risk factors have been identified. Here, the authors aimed to evaluate the risk of serious infections in RA patients initiating biological DMARD treatment in a real-world population.

Methods: A large real-world population was prospectively evaluated for serious infections and the associated risk factors. A total of 21 071 patients (median age 62 years; 74% women) were included. The incidence rate of serious infections and their risk factors were determined using a population-attributable fraction (PAF).

Results: Over a median follow-up of 2.1 years, 593 serious infections were reported, corresponding to an incidence rate of 28.2 per 1000 patient-years. The most common infections were respiratory (24.5%), followed by gastrointestinal (16.8%) and urinary (10.1%). The most significant risk factors for infections were age (OR 1.04 for each 1 year increase), male gender (OR 1.71), and previous infections (OR 2.64). The PAF for infections was 24.2% (95% CI 20.2-28.3), which was lower for ABA (20.9%) compared to TNFi (29.5%)

Conclusion: Abatacept was associated with a lower risk of serious infection compared to TNFi. The identification of risk factors for serious infections may guide the implementation of preventive strategies to reduce the burden of infections in RA patients initiating biological DMARD treatment.

Acknowledgments: This study was supported by AbbVie and Genentech, Inc.
Background: Patients with RA are at increased risk of infection compared with the general population, but it is unclear whether this is due to the underlying disease or to immunosuppressive medications used to manage the disease. Some biologic DMARDs (bDMARDs) have been associated with an increased risk of serious infection.² A large cohort study found no increased risk of serious infection in patients initiating abatacept compared with patients initiating other bDMARDs.³ It is clinically important to identify which patients are at a higher risk of infections at the time of initiating treatment with a bDMARD. However, studies that assess risk factors for infection and derive corresponding risk scores of infection, especially at the time of bDMARD treatment initiation, are lacking or based on too few patients.⁴

Objectives: To identify the risk factors for serious infections among patients with RA initiating treatment with a bDMARD in a real-world observational setting.

Methods: The Trouven MarketScan® Commercial and Supplemental Medicare databases were used to identify patients diagnosed with RA who initiated treatment with a bDMARD between January 2007 and December 2015. Patients were followed from treatment initiation until the occurrence of a serious infection requiring hospitalisation, the end of enrolment or 31 December 2015, whichever came first. The Cox proportional hazards model was used to estimate the hazard ratios (HRs) of serious infection associated with baseline risk factors including demographics, the presence of co-morbidities, prior hospitalised infections and medications. An infection risk score was developed using the independent risk factors found to be significant in the model.

Results: The study cohort included 84,308 patients initiating treatment with a bDMARD, mainly etanercept (36.7%), adalimumab (29.3%), infliximab (12.4%), rituximab (73%) and abatacept (6.8%). During a mean follow-up of 6.6 months, 1,724 patients were hospitalised for a serious infection (incidence rate 3.7/100 persons per year). The baseline risk factors significantly and independently associated with serious infections were age, prior hospitalisation for infection, hyper tension, diabetes, lymphoma, asthma, chronic obstructive pulmonary disease, cardiovascular disease, other autoimmune disease, corticosteroid use and anti-biotic use. The infection risk score, with a possible range of 0 to 15, had a mean (SD) value of 2.6 (1.9) with range 0–12.5. The HR (95% CI) of serious infection was 1.43 (1.40–1.45) for every unit increase in the risk score. Relative to patients with a score of 0, the HR (95% CI) of serious infection for a risk score of 5 was 5.9 (5.3–6.5), and for a risk score of 10 was 34.5 (28.5–41.6).

Conclusion: In this large, real-world cohort of patients with RA who were initiating treatment with a bDMARD, several patient characteristics were found to independently predict the subsequent risk of serious infection. The risk score, based on easily available patient characteristics, can be a simple and useful tool for the clinician to identify patients at higher risk of infection at the time of bDMARD initiation for the treatment of RA.

References:

Acknowledgments: Joanna Wright (editorial assistance), Caudex; funding: Bristol-Myers Squibb.

Disclosure of Interests: Samy Suissa Grant/research support from: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Consultant of: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis (advisory board meetings), Speakers bureau: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Paul Brassard: None declared, Alyssa L. Dominique Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, Teresa Simon Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb.

Objectives: This study aimed to evaluate the effectiveness of ABA on the clinical disease activity as well as the radiographic progression in patients with RA in the clinical settings.

Methods: All eligible patients were registered in the TBCR, a Japanese multicenter registry system for RA patients treated with biologics [3]. The present study included 553 consecutive patients whose ACPA data were obtained, treated with ABA and observed for longer than 52 weeks. We primarily compared the status of disease activity (SDAI) and radiographic progression (van der Heijde modified total Sharp score: mTSS) between ACPA-positive [ACP A (+)] and ACPA-negative [ACP A (-)] RA patients. The ACPA positive was defined as ≥13.5 U/ml of anti-CCP antibody.

Results: Number of cases was 446/107 [ACP A (+)/ACP A (-)], respectively. Baseline characteristics between groups were quite similar; mean age was 68.0/67.3 years, rate of methotrexate (MTX) use was 41.2%/50.0%, rate of bio-naïve was 28.0%/31.8%, and mean SDAI score was 22.2%/20.8. Significant difference was observed in mean change in SDAI score from baseline to 52 weeks between the ACPA (+) and ACPA (-) group (-13.4 vs -9.9, p = 0.027) (Figure 1A). Proportion of patients that achieved low disease activity (LDA; SDAI ≤11) at 52 weeks was significantly higher in the ACPA (+) group compared to the ACPA (-) group (72.1% vs 56.0%, p < 0.01) (Figure 1B). In univariate and multivariate logistic regression analysis, ACPA positivity was an independent predictor for achievement of LDA at 52 weeks (Table). There observed no significant difference between ACPA (+) and ACPA (-) group in the proportion of patients that achieved structural remission (ΔmTSS ≤0.5) at 52 weeks (66.2% vs 62.1%) (Figure 2A) as well as mean change in mTSS (1.66 vs 1.17), erosion score (0.60 vs 0.53), and joint narrowing (JSN) score (1.06 vs 0.64) (Figure 2B).

Table.

<table>
<thead>
<tr>
<th>Variables</th>
<th>OR (95% CI)</th>
<th>p-value</th>
<th>adjusted OR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.99 (0.98-1.01)</td>
<td>0.439</td>
<td>1.00 (0.97-1.02)</td>
<td>0.749</td>
</tr>
<tr>
<td>male (vs female)</td>
<td>1.09 (0.79-1.52)</td>
<td>0.643</td>
<td>0.97 (0.65-1.45)</td>
<td>0.511</td>
</tr>
<tr>
<td>disease duration</td>
<td>0.95 (0.76-1.19)</td>
<td>0.578</td>
<td>0.92 (0.73-1.17)</td>
<td>0.562</td>
</tr>
<tr>
<td>Biologics-naïve</td>
<td>1.09 (0.81-1.52)</td>
<td>0.486</td>
<td>1.19 (0.92-1.55)</td>
<td>0.178</td>
</tr>
<tr>
<td>Concomitant MTX use</td>
<td>1.12 (0.75-1.69)</td>
<td>0.649</td>
<td>1.14 (0.66-1.95)</td>
<td>0.732</td>
</tr>
<tr>
<td>Concomitant PSL use</td>
<td>0.71 (0.55-0.91)</td>
<td>0.008</td>
<td>0.88 (0.70-1.13)</td>
<td>0.310</td>
</tr>
<tr>
<td>SDAI @baseline</td>
<td>0.96 (0.94-0.99)</td>
<td>&lt;0.001</td>
<td>0.99 (0.96-1.01)</td>
<td>0.205</td>
</tr>
<tr>
<td>mHAD @baseline</td>
<td>0.50 (0.39-0.69)</td>
<td>&lt;0.001</td>
<td>0.60 (0.50-0.72)</td>
<td>0.005</td>
</tr>
<tr>
<td>ACPA positive</td>
<td>2.03 (1.29-3.17)</td>
<td>0.002</td>
<td>2.91 (1.96-4.31)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Bold italic, p<0.05

Conclusion: Consistent with previous reports, the ACPA-positive group demonstrated significantly higher LDA achievement rate at 52 weeks and indeed the ACPA positivity was significantly associated with LDA achievement in multivariate analysis. However, the ACPA-negative group demonstrated quite similar transition of SDAI score and LDA achievement rate except at 52 weeks compared with the ACPA-positive group. Additionally, there was no significant difference in the structural progression at 52 weeks between the groups. ABA treatment